MedPath

Effects of sitagliptin and vildagliptin on glucose fluctuations in patients with type 2 diabetes -prospective open-label controlled study

Phase 4
Conditions
type 2 diabetes mellitus
Registration Number
JPRN-UMIN000005627
Lead Sponsor
Department of Medicine II, Hokkaido University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1) patients who received insulin injection therapy 2) severe hepatic dysfunction, renal dysfunction, heart failure 3) history of anaphylaxis of Sitagliptin or Vildagliptin, 4) pregnancy and lactation 5) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate changes in MAGE; mean amplitude of glycemic excursions before and after switching from sitagliptin to vildagliptin, and vice versa
Secondary Outcome Measures
NameTimeMethod
1) M-value 2) fasting plasma glucose, HbA1c, glycoalbumin 3) beta cell function 4) changes in body weight, Body Mass Index, abdominal girth, blood pressure 5) several biomarkers
© Copyright 2025. All Rights Reserved by MedPath